Microvascular obstruction detection and therapy

1. A method for treating a microvascular thrombotic or spasmodic obstruction comprising:

locating a position of said microvascular thrombotic or spasmodic obstruction within a vasculature of a patient;

advancing a distal end of a treatment catheter through said vasculature and within proximity of said position of said microvascular thrombotic or spasmodic obstruction;

expanding an occlusion member within said vasculature;

delivering a treatment agent between said expanding occlusion member and said microvascular thrombotic or spasmodic obstruction so as to treat the microvascular thrombotic or spasmodic obstruction within the vasculature of the patient; and

monitoring treatment of said microvascular thrombotic or spasmodic obstruction, wherein monitoring comprises detecting materials released by the thrombotic or spasmodic obstruction as a result of delivery of the treatment agent.

2. The method of claim 1 , wherein said locating a position of said microvascular thrombotic or spasmodic obstruction within a vasculature of a patient is selected from a group of: magnetic resonance imaging, ultrasound imaging, pressure measurement, vascular impedance measurement and phasic flow measurement.

3. The method of claim 1 , wherein said expanding an occlusion member within said vasculature further comprises expanding a second occlusion member within said vasculature.

4. The method of claim 1 , wherein said expanding an occlusion member within said vasculature further comprises inflating an occlusion balloon.

5. The method of claim 1 , wherein said delivering a treatment agent between said expanding occlusion member and said microvascular thrombotic or spasmodic obstruction further comprises delivering one or more treatment agents selected from the following group: Factor X, factor VII, a IIB/IIIA agent, Tick Anticoagulant Peptide, echistatin, Integrilin, PPACK, DPG peptide inhibitor, TNK, streptokinase, urokinase, rTPA, adenosine, nitroglycerin, sodium nitroprusside, nicorandil, Hirulog, Bivalrudin, ReoPro, eptifibatide, TAP, Heparins, LMW Heparins, Argatroban, Hirudin, Refludan/Lepirudin (Berlex), Desirudin, recombinant forms, ABCIXIMAB, Eptifibatide, Tirofiban, Alteplase, Reteplase, Tenecteplase, Factor Xz, rivaroxaban, Fodaparinux, adenosine, anti-PMN antibodies, anti-leukocyte antibodies, quinolone agents, nitrogen mustard, hydroxyurea, anti-serotonin agents, such as cinanserin, pizotifen, cyproheptadine, lysenyl, mianserin, methysergide, promethazine, octreotide, trypsin, papain, chymotrypsin, lidocaine, quinidine, amiodarone, procainamide, propofenone, and beta blockade.

6. The method of claim 1 , wherein said delivering a treatment agent between said expanding occlusion member and said microvascular thrombotic or spasmodic obstruction further comprises disbursing said treatment agent through diffusion apertures of said catheter.

7. The method of claim 6 , wherein said disbursing said treatment agent through diffusion apertures of said catheter further comprises disbursing said treatment agent through a diffusion aperture region have a size gradient of said diffusion apertures.

8. The method of claim 1 , wherein said monitoring treatment of said microvascular obstruction further comprises measuring myocardial resistance.

9. The method of claim 8 , wherein said measuring myocardial resistance further comprises measuring flow and pressure of a fluid supplied between said expanding occlusion member and said microvascular thrombotic or spasmodic obstruction.

10. The method of claim 1 , wherein the detected materials comprise at least one of particulates, chemicals, proteins, blood cells, platelets, and emboli.

11. A method for treating a thrombotic or spasmodic obstruction of a microvascular vessel within a patient, comprising:

advancing a distal end of a guidewire to a location in communication with said thrombotic or spasmodic obstruction;

advancing a distal end of said treatment catheter over said guidewire to said location in communication with said thrombotic or spasmodic obstruction;

releasing a treatment agent from said treatment catheter so as to treat said thrombotic or spasmodic obstruction within the microvascular vessel of the patient;

monitoring an impedance of said microvascular vessel; and

stopping said releasing of said treatment agent when said impedance indicates removal of said thrombotic or spasmodic obstruction.

12. The method of claim 11 , wherein said monitoring an impedance of said microvascular vessel comprises determining an impedance by dividing a flow measurement of said treatment agent by a pressure measurement of a location in communication with said microvascular vessel.

13. The method of claim 12 , wherein said flow measurement comprises measuring a pressure differential between a fixed resistance in communication with said microvascular vessel.

14. The method of claim 13 , wherein said pressure measurement of a location in communication with said microvascular vessel is measured with a pressure transducer coupled to said treatment catheter.

15. The method of claim 11 , further comprising exposing said thrombotic or spasmodic obstruction to ultrasonic energy.